Meeting
2011 ASCO Annual Meeting
Exonic expression variations of EGFR and KRAS in small bronchoscopic biopsies from patients with advanced non-small cell lung cancer treated by combined bevacizumab/erlotinib therapy followed by platinum-based chemotherapy at disease progression: A multicenter phase II trial SAKK19/05.
Authors
M. H. Brutsche
Division of Pneumology, Kantonsspital St. Gallen, St. Gallen, Switzerland
M. H. Brutsche , M. Frueh , S. Crowe , K. J. Na , C. Droege , D. C. Betticher , R. von Moos , F. Zappa , M. Pless , L. Bubendorf , F. Baty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Prognostic Factors
Clinical Trial Registration Number
NCT00354549
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10570)
Abstract #
10570
Poster Bd #
24E
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients (pts).
First Author: Charu Aggarwal
Poster
2012 ASCO Annual Meeting
SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa).
First Author: Howard Jack West
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu